Authors:
Yoshisue, K
Nagayama, S
Shindo, T
Kawaguchi, Y
Citation: K. Yoshisue et al., Effects of 5-flourouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats, J PHARM EXP, 297(3), 2001, pp. 1166-1175
Authors:
Ikeda, K
Yoshisue, K
Matsushima, E
Nagayama, S
Kobayashi, K
Tyson, CA
Chiba, K
Kawaguchi, Y
Citation: K. Ikeda et al., Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro, CLIN CANC R, 6(11), 2000, pp. 4409-4415
Authors:
Yoshisue, K
Hironaga, K
Yamaguchi, S
Yamamoto, A
Nagayama, S
Kawaguchi, Y
Citation: K. Yoshisue et al., Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeatedsimultaneous administration of potassium oxonate (Oxo) in rats, CANC CHEMOT, 46(1), 2000, pp. 51-56
Authors:
Yoshisue, K
Yamamoto, Y
Yoshida, K
Saeki, M
Minami, Y
Esumi, Y
Kawaguchi, Y
Citation: K. Yoshisue et al., Pharmacokinetics and biological fate of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate (MET-88), a novel cardioprotective agent, in rats, DRUG META D, 28(6), 2000, pp. 687-694
Authors:
Yoshisue, K
Masuda, H
Matsushima, E
Ikeda, K
Nagayama, S
Kawaguchi, Y
Citation: K. Yoshisue et al., Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine,and potassium oxonate) to rats, DRUG META D, 28(10), 2000, pp. 1162-1167